AHA blog: PhRMA-led coalition seeks to dismantle 340B at patients’ expense
The Pharmaceutical Research and Manufacturers of America’s new ASAP 340B coalition “is another misguided attempt by drug companies to dismantle the 340B Drug Pricing Program so that they can continue to pad their billion-dollar bottom lines,” writes Bharath Krishnamurthy, director of health analytics and policy for the AHA. “The self-serving policy proposals outlined by this new alliance directly contravene Congress’ oft-demonstrated intent to preserve the 340B program over the last 30 years. Those most impacted by this coalition’s assault on 340B are the millions of patients who will lose access to lifesaving medicines and to other vital health care services supported by the program.” READ MORE
Related News Articles
Headline
The AHA, 340B Health, Maryland Hospital Association and Mid-Atlantic Association of Community Health Centers July 9 filed an amicus brief in a federal district…
Headline
In a letter submitted July 2 to the Centers for Medicare & Medicaid Services on guidance for the Medicare Drug Price Negotiation Program, the AHA expressed…
Headline
A Mississippi judge July 1 denied Novartis Pharmaceuticals’ and PhRMA’s request for a preliminary injunction against enforcement of state law protecting 340B…
Headline
The AHA, 340B Health, the Maryland Hospital Association and the Mid-Atlantic Association of Community Health Centers June 26 filed an amicus brief in a federal…
Headline
The AHA, along with 340B Health, the Mississippi Hospital Association and the Rural Hospital Alliance filed an amicus brief June 18 in the U.S. District…
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…